Iterum Therapeutics (NASDAQ:ITRM) Receives Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the stock. Iterum Therapeutics Stock Up 17.8 % Shares of NASDAQ ITRM opened at $1.49 on Wednesday. The company has a quick […]
More Stories
Top DevOps Testing Tools for Faster Software Delivery in 2026
Most teams don’t have a testing problem. They have a speed problem. DevOps Testing Tools promise faster feedback loops, but...
Long Story Short Season 2 Is Renewed! Release Date, Plot, and More
Netflix has recently given anime fans a major reason to celebrate by renewing Long Story Short for a new season....
MGA, Curaçao, and German Licences: What the Differences Mean for Users
Choosing an online casino often comes down to one detail most players skim past: the licence badge in the footer....
Is I Will Find You Season 2 Returning? Renewal Status, Cast, and Plot
In 2026, the first season of the popular and most awaited series was released. I Will Find You first dropped...
Top Ahrefs SEO Tools to Boost a Website’s Traffic and Sales
Website analysis has become one of the most useful SEO tools used by several companies nowadays. Ahrefs SEO tool provides...
Planning Group Travel That Doesn’t Fall Apart at the Logistics Stage
Anyone who has organized transportation for a wedding party, a school trip, or a corporate retreat knows the pattern. The...